Dendreon Corporation · Seattle, WA United States (NASDAQ: DNDN)
| 3005 1st Ave. | Phone: 206-256-4545 |
| Seattle, WA | Fax: 206-256-0571 |
| 98121 | |
| United States | 
Map This Company |
Dendreon Corporation Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Dendreon wants to boost your immunity from the start. It is developing therapeutic vaccines that help the body's immune system fight cancer by targeting dendritic cells, which initiate an immune response to disease-causing antigens. Its sole commercial product, Provenge, is a therapeutic vaccine that targets prostate cancer. Provenge gained the status of being the first therapeutic cancer vaccine to receive
Dendreon Corporation Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: DNDN Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 1,497 |
Executives
125 executives listed for Dendreon Corporation's Seattle, WA location.
| Chairman | Richard Brewer | |
|---|---|---|
| President, CEO, and Director | Mitchell Gold | |
| EVP and CFO | Gregory Schiffman |